Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Evercore ISI Group analyst Cory Kasimov maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $135 to $130.